(RTTNews) - Helus Pharma (HELP), a clinical stage pharmaceutical company, Tuesday announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.
Cola has more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals and was most recently, the CEO of Avalo Therapeutics.
"With highly differentiated HLP003 clinical data already in hand and a robust pipeline of novel compounds in development, Helus is uniquely positioned to advance a new paradigm in the treatment of serious mental health disorders. I'm excited to work alongside the Board and the Helus team to build on this foundation and translate scientific progress into lasting patient and shareholder impact.", commented Michael Cola.
In pre-market activity, HELP shares were trading at $6.35, up 0.47% on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
